EGFR and glioblastoma: Preliminary studies have shown that 90%–100% of EGFR-amplified GBM also have TERTp mutations, suggesting a potential cooperative role in driving tumorigenesis (Killela et al., 2013; Labussiére et al., 2014; Aibaidula et al., 2017).